4-Octyl itaconate suppresses IFN-γ–induced MHC II expression in bone marrow–derived macrophages
The Journal of Immunology · 2026-10-01 · 215 (10)
DOI: 10.1093/jimmun/vkag255 ↗Abstract
Abstract Macrophages function as professional antigen-presenting cells that integrate inflammatory signals with metabolic reprogramming to shape immune responses. Itaconate, an immunometabolite derived from ACOD1/IRG1 activity in activated macrophages, has been implicated in the regulation of inflammatory responses, yet its role in interferon γ (IFN-γ)–driven antigen presentation programs remains incompletely understood. Here, we demonstrate that the itaconate derivative 4-octyl itaconate (4-OI) suppresses IFN-γ–induced antigen presentation programs in bone marrow-derived macrophages. 4-OI reduced surface major histocompatibility complex class II (MHC II) expression and downregulated key components of the antigen presentation machinery, including CIITA, H2-Ab1, and H2-Eb1. Transcriptomic analysis revealed broad suppression of IFN-γ–responsive immune pathways, particularly those associated with antigen processing and inflammatory signaling. Mechanistically, 4-OI attenuated IFN-γ–induced phosphorylation of JAK1, JAK2, and STAT1, and pharmacological inhibition of JAK signaling phenocopied its effects on MHC II expression, implicating involvement of the IFN-γ–JAK–STAT1–CIITA axis. In vivo, 4-OI similarly reduced IFN-γ–induced MHC II expression in splenic macrophages, accompanied by decreased PD-L1 expression as a parallel marker of macrophage activation. Together, these findings identify 4-OI as an immunometabolic regulator of IFN-γ–driven macrophage activation, associated with modulation of the JAK–STAT1–CIITA signaling axis and suppression of antigen presentation programs.
EUVIMED